Skip to content

Survodutide vs Tirzepatide

Updated 7 sources

Key differences

  1. 1Tirzepatide hits GLP-1 and GIP. Survodutide hits GLP-1 and glucagon, which adds a direct liver fat effect.
  2. 2Tirzepatide is FDA approved as Mounjaro and Zepbound. Survodutide is not approved anywhere.
  3. 3No head-to-head trial. Headline numbers: tirzepatide 20.9% at 72 weeks (SURMOUNT-1) vs survodutide 16.6% at 76 weeks (efficacy estimand).

Side by side

Facts from each record, in the same words as their own pages.
Survodutide and Tirzepatide side by side
SurvodutideTirzepatide
Category
  • GLP-1, Weight loss
  • GLP-1, Weight loss
Evidence
  • Strong human trials
  • Strong human trials
FDA status
  • In clinical trialsRegulatory
  • FDA approved as Mounjaro +1Regulatory
WADA
  • Not confirmed
  • Not prohibited
Half-life
  • About 6 to 7 days, an estimate from one guide. We found no published human half-life figure.Competitor guide
  • About 5 days (Mounjaro label); 5 to 6 days in people with obesity or sleep apnea (Zepbound label). That is why it is dosed once a week.Regulatory
Routes
  • Subcutaneous injection
  • Subcutaneous injection
Forms
  • Vial (powder), Other form
Not reported
Reported doses
  • 0.3 to 6 mg (subcutaneous injection)
  • 0.25 to 15 mg (subcutaneous injection)
Most cited frequency
  • Once weekly, stepped up to a target of 3.6 or 6.0 mg, then held to week 76
  • Once weekly. Step up 2.5 mg after at least 4 weeks only if needed, then hold the maintenance dose.
Vial sizes
  • 5 mg, 6 mg, 10 mg, 20 mgCompetitor guide
  • 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mgCompetitor guide
Mixed vial keeps
  • Keep the mixed vial in the fridge at 2 to 8 C, away from light, and do not freeze and thaw it.Competitor guide
  • Keep the mixed vial in the fridge and use it within about 28 days.Competitor guide
Protocols on file
  • 10
  • 12

Doses shown are what sources report, labelled by origin. Not medical advice.

Read each in full

Sources

7 sources, each checked by date. Record updated Oct 24, 2026. Numbers are restated in our own words and labelled by where they came from.

Clinical study1

  1. Survodutide delivers 16.6% weight loss in major phase 3 obesity trialPharmaTimes, via a news report · checked Oct 24, 2026

Regulatory4

  1. Mounjaro and Mounjaro KwikPen label, rev. 8/2026DailyMed · checked Oct 24, 2026
  2. Zepbound Prescribing Information, rev. 04/2026FDA · checked Oct 24, 2026
  3. Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two phase III trials in MASH for survodutideBoehringer Ingelheim (via BioSpace), via a news report · checked Oct 24, 2026
  4. WADA 2026 Prohibited ListWADA · checked Oct 24, 2026

Competitor guide2

  1. Survodutide Dosing Guide: Trial Titration, Reconstitution & Side Effects (2026)Peptide Dosing Protocols · checked Oct 24, 2026
  2. Survodutide dosingPeptide Protocol Wiki · checked Oct 24, 2026